Orion's sales up by 4% in nine months
This article was originally published in Scrip
Executive Summary
Sales ofOrion, the Finnish pharmaceutical and diagnostics company, grew by 4% to €530.1 million in the first nine months of this year. It said the main reasons for slower growth included the weakening of the US dollar and the termination of a marketing licence for Calcimagon (calcium carbonate plus cholecalciferol), an osteoporosis therapy, in Germany.